Amgen

downturn economy markets bank negative fall down

Amgen-Zai stomach cancer asset loses OS benefit in final analysis

The final analysis in a phase 3 study of Amgen's Zai Labs-partnered bemarituzumab showed that the drug's benefits had lessened from the interim analysis.

Zoey Becker Sep 3, 2025 4:33pm

Glowing puzzle piece fitting into puzzle

Amgen looks to level up clinical trials with Veeva pact

Sep 2, 2025 3:05pm

blueprint construction hard hat hammer build

Amgen unveils plans for $600M R&D site in California

Sep 2, 2025 11:08am

Fierce Pharma

FDA's response letter salvo sheds light on drug refusal process

Jul 11, 2025 10:15am

Close up shot of the target from a dart game

Amgen, Zai say stomach cancer candidate hits phase 3 mark

Jun 30, 2025 10:36am

positive negative up down good bad mixed

Amgen's ph. 3 MariTide studies will ramp up dosing to quell nausea

Jun 24, 2025 9:59am